Yale Jen

On Monday, Mast Therapeutics Inc (NYSE: MSTX) provided an update on its business strategy and the clinical development of its product candidate AIR001. Laidlaw’s Yale Jen maintains a Neutral rating on the company. Update “Management reiterated that MSTX will focus on clinical...